![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Bates S, Green I, Hirsh J, Ginsberg J. Use of antithrombotic agents during pregnancy: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 627S–644S
- Elkayan U. Pregnancy through a prosthetic heart valve. Journal of the American College of Cardiology 1999; 33: 1642–1645
- Mahesh B, Evans S, Bryan A J. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. Failure of low molecular weight heparin in the prevention of prosthetic mitral valve thrombosis during pregnancy: case report and a review of options for anticoagulation. Journal of Heart Valve Disease 2002; 11: 745–750
- Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valves prostheses. Journal of the American College of Cardiology 1996; 27: 1698–1703
- Sbarouni E, Oakley C M. Outcome of pregnancy in women with valve prostheses. British Heart Journal 1994; 71: 196–201
- Weitz J L. Low molecular weight heparins. New England Journal of Medicine 1997; 337: 668–698